



REGULATION OF COLLAGENASES MATRIX
METALLOPROTEINASES WITH CTCF/YB-1
TRANSCRIPTION FACTORS IN HUMAN MALIGNANT
MELANOMA CANCER *IN VITRO*

BY

WISAM NABEEL IBRAHIM

A thesis submitted in fulfilment of the requirement for the
degree of Doctor of Philosophy

Kulliyyah of Allied Health Sciences
International Islamic University Malaysia

September 2018

ABSTRACT

The invasiveness of malignant melanoma is mainly attributed to the enzymatic destruction of the extracellular matrix and basement membrane components by a group of enzymes known as matrix metalloproteinases (MMPs). The expression of these proteinases is mainly regulated at the transcriptional level; therefore, high expression of MMPs is mainly attributed to different transcription factors which enhance or inhibit the promoter activity of *MMPs* genes. Among these factors, YB-1 and CTCF proteins are transcription factors in which CTCF is mainly a tumour suppressor protein; while YB-1 is an oncogenic factor and a prognostic indicator in a wide range of tumours that regulates most of the cancer processes such as proliferation, invasion and metastasis by regulating the expression of genes related to those processes. However; the expression of these transcription factors and their potential effect on the expression of collagenases MMPs in malignant melanoma cells are not yet confirmed. Therefore, this study was conducted to determine the expression of collagenases MMPs (*MMP1*, *MMP8* and *MMP13*), *YB-1* and *CTCF* transcription factors in A375 melanoma cancer cells. In addition, the stromal effect of normal skin fibroblasts on the expression of collagenases and proliferation in A375 cell was determined. The results of this experiment demonstrated an increase in the expression of *YB-1*, *MMP8* and *MMP13* in A375 cells. Thereafter, this was followed by the establishment of YB-1 silenced strain of A375 cells using a silencing short hairpin RNA (shRNA) construct. The effect of YB-1 knockdown on the expression of collagenases MMPs was determined using reverse transcription PCR and Western blotting. In addition, the antiproliferative effect was determined using flow-cytometry, colorimetric MTT assay and cell counting; while the anti-invasive properties were determined using wound healing assay. The results of this experiment elucidated that YB-1 protein regulates the expression of *MMP13*, cell cycle progression, cell proliferation and cell migration of A375 cancer cells *in vitro*. Therefore, the direct interaction between YB-1 protein and the AP-1 promoter sequence of *MMP13* was evaluated using Chromatin Immunoprecipitation assay (ChIP). The ChIP analysis has confirmed no interaction between YB-1 protein and the AP-1 promoter sequence. Finally, these experiments demonstrated *YB-1*, *MMP8* and *MMP13* were highly expressed in the A375 cancer cells. The stromal cells were found to promote A375 cell proliferation and enhance the expression of *MMP1*. In addition, YB-1 silencing was significantly associated with reduced expression of MMP13 enzyme, reduction in cancer cell proliferation in a cell cycle specific manner and anti-invasive properties. Therefore, YB-1, MMP13 and stromal cells are considered as promising elements that might help as a potential target in the treatment of melanoma tumour due to their roles in the processes of invasion, migration and proliferation. Further experiments are needed to demonstrate novel protein partners of YB-1 and novel binding sites within gene promoter region of *MMP13* with determination of the involved signalling pathways.

خلاصة البحث

إن سرطان الجلد الميلانيني هو أحد أشد أنواع سرطان الجلد خطورة من ناحية الانتشار، مسببا معدلات أعلى من الوفيات من بين الأنواع الأخرى من الأورام الخبيثة. ويعزى هذا السلوك السرطاني الى التحلل الانزيمي المصاحب في مكونات الغشاء القاعدي للنسيج بواسطة مجموعة من الانزيمات تعرف بانزيمات تحطيم النسيج البروتيني او الـ(ام ام بيس). هذا النوع من الانزيمات مهمة في العديد من العمليات الحيوية والفسولوجيه كتطور الجنين والتئام الجروح، ولكن فعاليات هذه الانزيمات المفرطه تساهم في تكوين وانتشار العديد من الاورام السرطانية. مستوى فرز هذه الانزيمات وفعاليتها يعتمد بصورة رئيسيه على معدل النسخ الجيني، ولذلك فان هذه الدراسه تهدف الى قياس مستوى تكوين انزيمات الـ(ام ام بي 1)، الـ(ام ام بي 8) والـ(ام ام بي 13)، بالاضافة الى عوامل الاستنساخ الـ(واي بي 1) والـ(سي تي سي اف) والتي تعتبر من البروتينات الفعاله في تقدم الاورام السرطانيه من خلال تنظيم الاستنساخ الجيني في الخلايا السرطانيه. لقد اثبتت الدراسه زياده في افراز انزيمات الـ(ام ام بي 8)، الـ(ام ام بي 13) وعامل الاستنساخ الـ(واي بي 1) ولذلك كانت التجربه اللاحقه هي انشاء خلايا سرطان ميلانيني مع التثبيط الدائم لعامل النسخ الجيني الـ(واي بي 1) باستخدام تقنيه تكوين احماض نوويه قصيره مكمله لاحماض الـ(واي بي 1) النوويه حيث تم التأكد من التثبيط لاحقا بقياس مستوى الحمض النووي ومستوى بروتين الـ(واي بي 1). بالاضافة الى ذلك تم دراسه تاثير التثبيط على مستوى التكوين الجيني والبروتيني للانزيمات المحطمة الثلاث. أيضا تمت دراسة تاثير التثبيط على سرعه تكاثر الخلايا السرطانيه وقدرتها على الاقتحام الموضعي. ولقد أثبتت هذه الدراسه ان تثبيط الـ(واي بي 1) الدائم يسبب نقص في افراز انزيم الـ(ام ام بي 13) ويسبب تدريجياً في تكاثر الخلايا السرطانيه ويحدد من قابليتها على الاقتحام ولذلك تم اجراء تجربه اخرى لتقييم التفاعل المباشر بين المنطقه المنظمه في جين انزيم الـ(ام ام بي 13) التي تعرف بالـ(اي بي 1) وبين بروتين الـ(واي بي 1) من خلال استخدام تقنية الترسيب المناعي للكروماتين والذي اثبت وجود المنطقه في المكون الجيني للخلايا ولكن عدم تفاعله مع بروتين الـ(واي بي 1) ولذلك اثبتت هذه الدراسه الدور الرئيسي لبروتين الـ(واي بي 1) في تنظيم افراز انزيم الـ(ام ام بي 13) وفي تنظيم التكاثر والانتشار لخلايا سرطان الجلد الميلانيني. ولذلك يعتبر بروتين الـ(واي بي 1) هدف علاجي مهم قد يؤدي إلى علاج مرضى سرطان الجلد الميلانيني.

APPROVAL PAGE

The thesis of Wisam Nabeel Ibrahim has been approved by the following:

Associate Prof. Dr Mohammad Syaiful Bahari bin Abdull Rasad
Supervisor

Associate Prof. Dr. Ridhwan Bin Abdul Wahab
Co-Supervisor

Associate Prof. Dr. Muhammad Bin Ibrahim
Co-Supervisor

Assistant Prof Dr.Mohd Arifin Kaderi
External Examiner

Professor Shahrarum Shamsuddin
External Examiner

Professor Teh Lay Kek
External Examiner

Associate Prof. Dr Jesni Shamsul Shaari
Chairman

DECLARATION

I hereby declare that this dissertation is the result of my own investigations, except where otherwise stated. I also declare that it has not been previously or concurrently submitted as a whole for any other degrees at IIUM or other institutions.

Wisam Nabeel Ibrahim

Signature

Date

**DECLARATION OF COPYRIGHT AND AFFIRMATION OF
FAIR USE OF UNPUBLISHED RESEARCH**

**REGULATION OF COLLAGENASES MATRIX
METALLOPROTEINASES AND ITS INTERACTING
PARTNERS CTCF/YB-1 TRANSCRIPTION FACTORS IN
HUMAN MALIGNANT MELANOMA CANCER *IN VITRO***

I declare that the copyright holders of this dissertation are jointly owned by the student and IIUM.

Copyright © 2018 Wisam Nabeel Ibrahim and International Islamic University Malaysia. All rights reserved.

No part of this unpublished research may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without prior written permission of the copyright holder except as provided below

1. Any material contained in or derived from this unpublished research may be used by others in their writing with due acknowledgement.
2. IIUM or its library will have the right to make and transmit copies (print or electronic) for institutional and academic purposes.
3. The IIUM library will have the right to make, store in a retrieved system and supply copies of this unpublished research if requested by other universities and research libraries.

By signing this form, I acknowledged that I have read and understand the IIUM Intellectual Property Right and Commercialization policy.

Affirmed by Wisam Nabeel Ibrahim

.....
Signature

.....
Date

DEDICATION

“To my beloved parents for their support and to my beloved wife for her patience and support “

ACKNOWLEDGEMENT

By the name of Allah, I praise him with gratitude for his guidance and his blessings which helped me to pass through all the difficulties and challenges to complete this thesis.

I wish to express my appreciation and thanks to my supervisor Associate Prof. Dr Mohammad Syaiful Bahari for his valuable guidance, motivation and wisdom. I would like to thank him for his constructive comments and his time in evaluating this thesis, and for that, I will be forever grateful.

In addition, I wish to express my gratitude to Associate Professor Dr. Ridhwan Bin Abdul Wahab for his valuable encouragement and guidance in this study.

To Professor Dr. Ridzwan Bin Hashim and Associate Prof. Dr. Muhammad Bin Ibrahim thank you for your guidance and support in this study.

To the dedicated and supportive science officers and assistant science officers in Kulliyah of Allied Health Sciences, thank you for your support in this project in providing guidance and appropriate laboratory setting to complete this project.

This project was supported by the Research Initiative grant Scheme 2015 (RIGS15-089-0089) and (FRGS 11-039-0188).

Finally, a special thanks to those who provided their time, effort and support for this project.

TABLE OF CONTENTS

Abstract	ii
Abstract in Arabic	iii
Approval page	iv
Declaration	v
Copyright	vi
Dedication	vii
Acknowledgement	viii
Table of contents	ix
List of tables	xiv
List of figures	xv
List of symbols	xviii
List of abbreviations	xix

CHAPTER ONE: INTRODUCTION 1

1.1 Background of the study	1
1.2 Summary of thesis	3
1.3 Problem statement	5
1.4 Significance of the study	6
1.5 Objective	7
1.5.1 General objective	7
1.5.2 Specific objectives	7

CHAPTER TWO: LITERATURE REVIEW 8

2.1 Cancer biology	8
2.2 Malignant melanoma	10
2.2.1 Background	10
2.2.2 Molecular pathways in malignant melanoma	11
2.3 Matrix metalloproteinases	13
2.3.1 Introduction	13
2.3.2 Matrix metalloproteinases and cancer	17
2.3.2.1 Matrix metalloproteinases secretion within the tumour microenvironment	17
2.3.2.2 Functions of matrix metalloproteinases in cancer	18
2.3.3 Collagenases MMPs	22
2.3.3.1 Structure of collagenases	22
2.3.3.2 Action of collagenases	23
2.3.3.3 Collagenase-1 (MMP1)	25
2.3.3.4 Collagenase-2 (MMP8)	25
2.3.3.5 Collagenase-3 (MMP13)	26
2.3.4 Regulation of collagenases activity	28
2.3.4.1 Transcriptional regulation of collagenases	28
2.3.4.2 Genetic polymorphisms	34
2.3.4.3 Epigenetic regulation	35
2.3.4.4 mRNA stabilization	36
2.3.4.5 Post-translational activation	36

2.3.4.6 Tissue inhibitors of matrix metalloproteinases (TIMPs) ..	36
2.3.4.7 Summary	37
2.4 CTCF protein	37
2.5 YB-1 protein	41

CHAPTER THREE: MATERIALS AND METHODS45

3.1 Materials	45
3.1.1 Disposable items	45
3.1.2 Instruments and apparatus	45
3.1.3 Chemicals and reagents	45
3.2 General study design	50
3.3 Methodology	52
3.3.1 Cell culture	52
3.3.1.1 Thawing procedure	52
3.3.1.2 Subculture procedure	53
3.3.1.3 Cryopreservation procedure	54
3.3.1.4 Coculture setting	54
3.3.2 Reverse transcriptase quantitative polymerase chain reaction (RT-qPCR)	55
3.3.2.1 RNA extraction	55
3.3.2.2 RNA quantity and purity	56
3.3.2.3 RNA integrity	57
3.3.2.4 cDNA synthesis from RNA samples	57
3.3.2.5 Running the RT-qPCR	58
3.3.3 Western blotting	64
3.3.3.1 Preparation of protein lysate sample	64
3.3.3.2 Quantification of protein concentration	65
3.3.3.3 Protein sample preparation	66
3.3.3.4 SDS polyacrylamide gel electrophoresis	66
3.3.3.5 SDS polyacrylamide gel staining	68
3.3.3.6 Blotting protocol	69
3.3.4 Assessment of A375 cell proliferation	74
3.3.4.1 Serial trypan blue cell counting	74
3.3.4.2 MTT assay	76
3.3.4.3 Flow cytometry - cell cycle assay	77
3.3.5 Establishment of YB-1 knocked down strains of A375 cells	78
3.3.5.1 Preparation of LB broth liquid medium	78
3.3.5.2 Preparation of LB agar plates	78
3.3.5.3 Transformation of E. coli	79
3.3.5.4 Amplification and extraction of plasmid DNA	80
3.3.5.5 Plasmid quality and quantity	82
3.3.6 Transfection of A375 melanoma cells	82
3.3.6.1 Determination of puromycin kill curve	82
3.3.6.2 Plasmid transfection of A375 melanoma cells	83
3.3.6.3 Confirmation of YB-1 knockdown	87
3.3.7 Cell migration assay (Wound healing assay)	88
3.3.8 Chromatin Immunoprecipitation assay (ChIP)	88
3.3.8.1 The analysis of chromatin digestion	92
3.3.9 Statistical analysis	93

CHAPTER FOUR: EXPRESSION OF COLLAGENASES MATRIX METALLOPROTEINASES IN A375 MELANOMA CELLS.....	94
4.1 Introduction.....	94
4.2 Literature review.....	95
4.2.1 Stromal cells in the tumor environment.....	95
4.2.2 Collagenases MMPs.....	96
4.2.3 YB-1 oncogenic factor and CTCF protein.....	96
4.3 Objective.....	98
4.3.1 General objective.....	98
4.3.2 Specific objectives.....	98
4.4 Materials and methods.....	98
4.4.1 Study design.....	98
4.4.2 Cell culture conditions.....	100
4.4.3 Screening of MMPs expression using an RT-qPCR array.....	100
4.4.4 Expression of collagenases MMPs, YB-1 and CTCF in A375 melanoma cells.....	100
4.4.4.1 Coculture setting.....	102
4.4.4.2 Cell quantification.....	102
4.4.4.3 Determination of gene and protein expression levels.....	102
4.5 Results.....	103
4.5.1 Morphology.....	103
4.5.2 RNA extraction and RT-qPCR amplification.....	107
4.5.3 RT-qPCR array results.....	111
4.5.4 Coculture and A375 Cell Proliferation.....	114
4.5.5 RT-qPCR analysis.....	117
4.5.6 Protein expression analysis.....	121
4.5.6.1 Quantification of protein concentration.....	121
4.5.6.2 Western blotting analysis.....	123
4.6 Discussion.....	125
4.6.1 Western blotting.....	125
4.6.1.1 Internal control.....	125
4.6.1.2 Target proteins.....	126
4.6.2 RT-qPCR.....	127
4.6.2.1 Housekeeping genes.....	127
4.6.2.2 Target genes.....	128
4.6.3 A375 melanoma / CCD-1079 skin fibroblast coculture.....	129
4.6.3.1 CCD-1079SK skin fibroblast cells as a model for stromal cells.....	129
4.6.3.2 Fibroblast cells enhanced the proliferation of A375 melanoma cells in vitro.....	130
4.6.3.3 Fibroblast cells enhanced MMP1 expression in A375 melanoma cells in vitro.....	131
4.6.4 Expression of collagenases MMPs in A375 melanoma cells.....	132
4.6.5 YB-1 protein is highly expressed in A375 Melanoma cells.....	134
4.6.6 CTCF expression in A375 cells.....	135
4.7 Conclusion.....	136

CHAPTER FIVE: YB-1 KNOCKDOWN IN A375 MELANOMA CELL	
LINE.....	138
5.1 Introduction.....	138
5.2 Literature review.....	138
5.2.1 Introduction.....	138
5.2.2 RNA interference.....	139
5.2.3 YB-1 protein and the expression of collagenases MMPs.....	140
5.2.4 YB-1 protein and the cancer cell proliferation.....	141
5.2.5 YB-1 protein and the cell cycle in cancer cell.....	142
5.2.6 YB-1 protein and cancer cell migration.....	143
5.3 Objective.....	145
5.3.1 General objective.....	145
5.3.2 Specific objectives.....	145
5.4 Materials and methods.....	145
5.4.1 Study design.....	145
5.4.2 Cell culture and shRNA plasmid transfection.....	147
5.4.3 Validation of YB-1 knockdown in silenced cell strains.....	147
5.4.4 A375 cell proliferation assay and cell cycle interference.....	147
5.4.5 Expression of collagenases MMPs.....	148
5.4.6 A375 cell migration assay.....	148
5.5 Results.....	148
5.5.1 Puromycin kill curve.....	148
5.5.2 Confirmation of successful plasmid transfection in A375 cells...	150
5.5.3 Validation of YB-1 knockdown in A375 cells.....	152
5.5.4 RNA extraction and RT-qPCR amplification.....	154
5.5.5 Effect of YB-1 silencing on the expression of collagenases in A375 cell line.....	158
5.5.5.1 RT-qPCR.....	158
5.5.5.2 Western blotting analysis.....	160
5.5.6 Antiproliferative effect of YB-1 silencing in A375 cell line.....	162
5.5.7 Effect of YB-1 silencing on cancer cell cycle in A375 cell line...	164
5.5.8 Effect of YB-1 silencing on A375 cell line migration assay <i>in</i> <i>vitro</i>	166
5.6 Discussion.....	168
5.6.1 YB-1 silencing methodology.....	168
5.6.2 YB-1 protein and the expression of collagenases MMPs in A375 cancer cells.....	169
5.6.3 A375 cancer cell proliferation.....	170
5.6.3.1 Proliferation assays.....	170
5.6.3.2 YB-1 protein and A375 cancer cell proliferation.....	171
5.6.4 YB-1 protein and A375 cancer cell migration.....	172
5.7 Conclusion.....	173
CHAPTER SIX: INTERACTION WITH AP-1 PROMOTER	
SEQUENCE OF MMP13 GENE.....	175
6.1 Introduction.....	175
6.2 Literature review.....	175
6.2.1 Introduction.....	175
6.2.2 MMP13 gene promoter.....	176

6.2.3 AP-1 promoter site and the expression of MMP13	177
6.3 Objective.....	178
6.3.1 General objective	178
6.3.2 Specific objective.....	178
6.4 Materials and methods.....	178
6.5 Results	181
6.5.1 Micrococcal nuclease digestion of chromatin DNA.....	181
6.5.2 Chromatin immunoprecipitation assay	183
6.6 Discussion.....	185
6.7 Conclusion	187
CHAPTER SEVEN: DISCUSSION AND CONCLUSION	189
7.1 Introduction.....	189
7.2 Selection of Cell lines	189
7.3 Expression of MMPs, YB-1, CTCF and the stromal effect.....	190
7.4 YB-1 knock down with shRNA plasmid.....	195
7.5 YB-1 interaction with AP-1 sequence of MMP13 gene.....	196
7.6 Limitations	198
7.7 Recommendations.....	198
Bibliography	199
Appendices.....	221
9.1 Appendix 1 Quality control data of YB-1	221
9.2 Appendix 2 Quality control data of CTCF	222
9.3 Appendix 3 Quality control data of MMP1	223
9.4 Appendix 4 Quality control data of MMP8.....	224
9.5 Appendix 5 Quality control data of MMP13.....	225
9.6 Appendix 6 Quality control data of TIMP1.....	226
9.7 Appendix 7 Quality control data of TIMP2.....	227
9.8 Appendix 8 Quality control data of TIMP4.....	228
9.9 Appendix 9 Quality control data of α -tubulin	229
9.10 Appendix 10 Quality control data of RPL13A.....	230
9.11 Appendix 11 Quality control data of HPRT1	231
9.12 Appendix 12 Quality control data of GAPDH	232
9.13 Appendix 13 Quality control data of β 2-microglobulin	233
9.14 Appendix 14 Quality control data of β -actin	234
9.15 Appendix 15 Conference presentations and publications.....	235
9.15.1 Conferences.....	235
9.15.2 Publications	235

LIST OF TABLES

<u>Table No.</u>		<u>Page No.</u>
Table 3.1	List of disposable items	46
Table 3.2	List of instruments and apparatus	46
Table 3.3	List of chemicals and reagents	47
Table 3.4	Amplicons sequences of the validated target and housekeeping genes used in qPCR (Bio-Rad, USA)	61
Table 3.5	Reagents specifications used for the preparation of SDS polyacrylamide gels	67
Table 3.6	Buffers and specifications used in Western blotting protocol	70
Table 3.7	List of monoclonal antibodies used in the Western blotting protocol	73
Table 4.1	List of genes included in the matrix and adhesion molecules 96 PCR array	101

LIST OF FIGURES

<u>Figure No.</u>		<u>Page No.</u>
Figure 2.1	Classification of matrix metalloproteinases	14
Figure 2.2	Roles of MMPS in cancer development and progression	16
Figure 2.3	Structure of collagenase matrix metalloproteinases peptides	24
Figure 2.4	Structure of the promoter regions in collagenases genes	30
Figure 2.5	Domain structure of CTCF protein	38
Figure 2.6	Domain structure of YB-1 protein	42
Figure 3.1	The general study design	51
Figure 3.2	Extracellular Matrix and Adhesion Molecules Plate design	59
Figure 3.3	The designed customized 96 qPCR plate (Bio-Rad, USA)	62
Figure 3.4	Structure of retroviral pGFP-V-RS vector (OriGene, USA)	85
Figure 4.1	Study design to determine collagenases expression in A375 melanoma cells	99
Figure 4.2	Morphology of A375 malignant melanoma cells	104
Figure 4.3	Morphology of CCD1079 skin fibroblasts cells	106
Figure 4.4	Denaturing agarose gel electrophoresis of RNA samples	108
Figure 4.5	RT- qPCR SYBR green amplification curve	110
Figure 4.6	Melting curve analysis of RT- qPCR amplicons	110
Figure 4.7	Relative mRNA expression of MMPs genes in A375 cell line	112
Figure 4.8	Relative mRNA expression of TIMPs genes in A375 cell line	113
Figure 4.9	Microscopic growth and morphological changes of A375 melanoma cell line by the influence of fibroblasts cells	115

LIST OF FIGURES

<u>Figure No.</u>		<u>Page No.</u>
Figure 4.10	Growth curve for A35 cells in monoculture & coculture	116
Figure 4.11	Relative mRNA expression analysis of target genes in A375 melanoma cells and CCD-1079SK fibroblasts cells	118
Figure 4.12	Relative mRNA expression analysis of target genes of A375 melanoma cells and the coculture of A375 with CCD-1079SK fibroblasts cells	120
Figure 4.13	Standard curve of colorimetric Pierce BCA assay for calculation of protein concentration	122
Figure 4.14	Western blotting analysis of target genes in A375 melanoma cells, CCD1079SK fibroblasts cells and the coculture of both cell line	124
Figure 5.1	Flowchart of YB-1 shRNA silencing study	146
Figure 5.2	Puromycin kill curve observed in A375 melanoma cells	149
Figure 5.3	Validation of A375 cells transfection with pGFP-V-RS vector	151
Figure 5.4	YB-1 protein expression analysis using Immune fluorescence staining	153
Figure 5.5	Denaturing agarose gel electrophoresis of RNA samples	155
Figure 5.6	RT-qPCR SYBR green amplification curve	157
Figure 5.7	Melting curve analysis of RT qPCR amplicons	157
Figure 5.8	RT-qPCR analyses of YB-1 knockdown	159
Figure 5.9	Western blotting and densitometry analysis	161
Figure 5.10	Anti-proliferative effects of YB-1 shRNA	163
Figure 5.11	Flow cytometry cell cycle analysis	165
Figure 5.12	Effect of YB-1 shRNA on cancer cell migration	167
Figure 5.13	Epithelial-mesenchymal transformation in A375 melanoma cells	167

LIST OF FIGURES

<u>Figure No.</u>		<u>Page No.</u>
Figure 6.1	Workflow of chromatin immune precipitation assay	180
Figure 6.2	Agarose gel electrophoresis of digested chromatin products from A375 cells	182
Figure 6.3	Chromatin immunoprecipitation assay	184
Figure 7.1	Changes in the expression of MMPs, TIMPs and transcription factors	192
Figure 7.2	The proposed mechanism involved in the stromal regulation of MMP1 expression	194
Figure 7.3	The proposed mechanism involved in the regulation of MMP13 expression, cell proliferation, and epithelial-mesenchymal transition	197

LIST OF SYMBOLS

°C	Degree Celsius
%	Percentage
-	Minus
bp	Base pair
g	Gram
mg	Milligram
mM	Millimolar
mL	Millilitre
nm	Nanometre
NaCl	Sodium chloride
µg	Microgram
µL	Microliter
µM	Micromolar
ng	Nanogram
M	Molar
V	Volts
H ₂ O	Water
CO ₂	Carbon dioxide
MgCl ₂	Magnesium chloride
BSC	Biosafety cabinet

LIST OF ABBREVIATIONS

cDNA	Complimentary DNA
DAPI	4',6-diamidino-2-phenylindole
DMEM	Dulbecco's Modified Eagle Medium
DMSO	Dimethyl sulfoxide
dNTP	Deoxy nucleoside triphosphates
DNA	Deoxyribonucleic acid
RNA	Ribonucleic acid
EGF	Epidermal growth factor
FGF	Fibroblasts growth factor
PDGF	Platelets derived growth factor
KDGF	Keratinocyte growth factor
TGF- β	Tumour growth factor - β
TNF- α	Tumour necrosis factor - α
HGF	Hepatocytes growth factor
VEGF	Vascular endothelial growth factor
NGF	Nerve growth factor
MAPK	Mitogen activated phosphokinases
FITC	Fluorescein isothiocyanate
IgG	Immunoglobulin G
IgM	Immunoglobulin M
MMPs	Matrix Metalloproteinases
CTCF	CCCTC-binding factor

LIST OF ABBREVIATIONS

YB-1	Y-box binding protein
MMP13	Matrix Metalloproteinase 13
TIMPs	Tissue inhibitors of matrix proteinases
mRNA	Messenger ribonucleic acid
shRNA	Short hairpin ribonucleic acid
PBS	Phosphate buffer saline
PCR	Polymerase chain reaction
RT-PCR	Reverse transcriptase polymerase chain reaction
PFA	Paraformaldehyde
RT-qPCR	Quantitative reverse transcriptase polymerase chain reaction
TBE	Tris/Borate/EDTA buffer
TAE	Tris/Acetic acid/EDTA buffer
UV	Ultraviolet
ACTB	Actin Beta
B2M	Beta-2-Microglobulin
GAPDH	Glyceraldehyde-3-Phosphate Dehydrogenase.
HPRT1	Hypoxanthine Phosphoribosyltransferase 1
RPL13A	Ribosomal Protein L13a
TUBA1A	Alpha Tubulin
Abs.	Absorbance

CHAPTER ONE

INTRODUCTION

1.1 BACKGROUND OF THE STUDY

Malignant melanoma is the third most common malignant skin cancer and is the most serious cancer in terms of local invasiveness and mortality rate (Kumar, Abbas, Fausto, & Aster, 2014). While the incidence rate of this malignancy is constantly increasing worldwide (Yamashita et al., 2013), malignant melanoma is considerably associated with poor prognosis, with an estimated 10-year survival rate of less than 10% (Hall & Kudchadkar, 2014).

Cancer cells in general, possess a broad spectrum of migration and invasion mechanisms including the destruction of tissue basement membrane and extracellular matrix (ECM) components allowing the migration of cancer cells (Bourboulia & Stetler-Stevenson, 2010). The matrix metalloproteinases (MMPs) group of enzymes play a major role in this destruction process that participates in the remodelling of the ECM to support the growth of tumour cells (Moro, Mauch, & Zigrino, 2014). These proteinases are involved in remodelling processes of normal tissue such as in morphogenesis, angiogenesis, tissue repair and embryonic development (Kessenbrock, Plaks, & Werb, 2010). The secretion of these enzymes is tightly controlled to regulate these normal functions; in which imbalance between the inhibition and activation of MMPs results in disturbances characterized by an excessive degradation of the ECM such as in osteoarthritis, rheumatoid arthritis & different types of malignancies (Frank et al., 2012; Hadler-Olsen, Winberg, & Uhlin-Hansen, 2013; Moro et al., 2014; Nissinen & Kähäri, 2014). Within the tumour mass, MMPs are expressed by cancer cells and to a larger extent by the surrounding normal cells within the tumour environment known

as cancer stromal cells participating in the cleavage of ECM and basement membrane components (Hadler-Olsen et al., 2013; Hashimoto et al., 2016).

This family of enzymes is classified by their structure and substrate specificity into collagenases, gelatinases, stromelysins, and matrilysins (Gialeli, Theocharis, & Karamanos, 2011a). Collagenases MMPs include collagenases-1 (MMP1), collagenase-2 (MMP8) and collagenase-3 (MMP13) which are capable of initiating degradation of native fibrillary collagens (type I, II, III, V and IX) and obviously play a crucial role in degradation of collagenous extracellular matrix (ECM) in various tumours (Moro et al., 2014). Both MMP1 and MMP13 are associated with accelerated invasive processes by cancer cells and are either secreted by the cancer cells or the tumour surrounding stroma (Gialeli et al., 2011a; Kim et al., 2011; Martinet, Hirsch, Mulshine, & Vignaud, 2012). Meanwhile, MMP8 is associated with some controversial effects within cancer microenvironment ranging from a promoter to an inhibitor in different malignancies (Schröpfer et al., 2010a; Thirkettle et al., 2013).

Generally, the expression of these collagenases is regulated at different levels and mechanisms; however, the most influential mechanism of control is at the transcriptional level at the noncoding promoter sequence via the specific binding of different transcription factors (Brown & Murray, 2015). The AP-1 DNA binding sites among the regulatory sites are present in the gene promoters of *MMP1* and *MMP13* gene and are mainly responsible for the transcriptional regulation of collagenases expression (Samuel, Beifuss, & Bernstein, 2007; Xia et al., 2015; Lu et al., 2016). The transcriptional regulation at this gene site is believed to participate actively in the progression of cancer cells by its binding with different oncogenic transcription factors expressed in cancer cells causing an increase in the expression of collagenases (Kessenbrock, Wang, & Werb, 2015).

CTCF and YB-1 transcription factors are among the many transcription factors that are involved with different regulatory roles in cancer cell development and progression. These factors are capable of specific binding with different gene promoter sequences and thereby can transcriptionally control the expression of different genes responsible for cancer cell proliferation and growth (H. Wang et al., 2015; Chen et al., 2016). CTCF is a well-defined tumour suppressor protein mainly regulating the epigenetic changes in cancer cells (Kemp et al., 2014). While, the YB-1 transcription factor is an oncogenic factor that is involved in stimulating different hallmarks of cancer cells (Lasham, Woolley, Dunn, & Braithwaite, 2013; Kemp et al., 2014).

Although both transcription factors might work in the opposite manner; however, some studies reported their interaction with each other in a way that modifies their binding specificity with gene promoter sequences (Samuel et al., 2007; Wallace, 2007). Both factors were reported in the transcriptional regulation of MMPs through interaction with different promoter sequences including the AP-1 site (Abdull Rasad et al., 2008). However, the influence of these transcription factors on the expression of collagenases MMPs is not well elucidated in melanoma cells or other types of cancer cells. Therefore, this study would elucidate the possible mechanism regulating the expression of collagenases MMPs in A375 malignant melanoma cell line *in vitro* including YB-1, CTCF transcription factors and stromal cells in melanoma microenvironment *in vitro*.

1.2 SUMMARY OF THESIS

The aim of this study was to evaluate and discuss the expression of collagenases MMPs in malignant melanoma cancer cells and to determine novel mechanisms or transcription factors capable of regulating the expression of these enzymes.

In Chapter 1 and Chapter 2, all the theoretical background was provided to introduce the reader to cancer cells biology and to comprehensively describe the different regulatory aspects of the expression of MMPs from transcription to translation.

In Chapter 3, all the methods used in this study were described including the reagents, equipment and the basic protocols with their optimizations. The basic techniques of cell culture maintenance were fully described. In addition, the full description of reverse transcription polymerase chain reaction (RT-PCR) protocol and analysis were described in details. The Western blotting protocol with optimizations and the analysis were also fully described in this thesis. The description and explanation of plasmid transfection, validation, and maintenance of the cells was also described and finally, the protocol of chromatin immunoprecipitation (ChIP) assay was also described.

In Chapter 4, the expression of all *MMPs* and *TIMPs* were screened in the melanoma cancer cells followed by evaluating the expression of collagenases MMPs, YB-1 and CTCF proteins in melanoma cells and in the stromal- cancer cells model by the use of the human skin fibroblasts cells. The results were fully analysed and discussed in the Chapter which provided the preliminary data for the implementation of the next Chapter.

In Chapter 5, a stable strain of melanoma cells with constant knockdown of YB-1 was established, validated and tested for its influence on the expression of collagenases MMPs, cancer cell proliferation and invasion *in vitro*.

In Chapter 6, the potential interaction of YB-1 and CTCF with the AP-1 promoter sequence of MMP13 was determined *in ex vivo* using ChIP assay to elucidate the possible protein – DNA interactions and their possible regulation of collagenases expression.